5/7
04:20 pm
ys
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
High
Report
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
5/7
04:20 pm
ys
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
High
Report
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
4/29
08:00 am
ys
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Medium
Report
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
4/19
07:00 am
ys
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
High
Report
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
4/19
07:00 am
ys
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
High
Report
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
4/18
08:00 am
ys
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
High
Report
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
4/18
08:00 am
ys
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
High
Report
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
4/16
08:00 am
ys
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
Medium
Report
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
4/16
08:00 am
ys
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
Medium
Report
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
4/9
08:00 am
ys
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
High
Report
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
4/9
08:00 am
ys
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
High
Report
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
4/3
08:00 am
ys
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
High
Report
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
4/3
08:00 am
ys
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
High
Report
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
3/5
08:00 am
ys
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
High
Report
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
2/22
05:00 pm
ys
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024
Medium
Report
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024
2/16
08:20 pm
ys
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting
Medium
Report
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting